BRCA1主要转录起始位点上游区域的DNA甲基化是高grade浆液性卵巢癌患者的独立良好预后因素
研究建立了定量检测BRCA1主要转录起始位点上游区域DNA甲基化的方法,并在2011至2018年间92例新辅助化疗后的晚期高级别浆液性卵巢癌FFPE样本中分析甲基化与突变。BRCA1甲基化检出17/79(21.5%),BRCA1/2突变17/92(18.5%),RAD51C突变1/92(1.1%)。多因素分析显示BRCA1甲基化(P=0.038,HR=0.47,95%CI 0.21-0.96)和无残留肿瘤(P=0.012,HR=0.49,95%CI 0.28-0.85)均为显著良好预后因素。
要点
- 建立了定量检测BRCA1主要转录起始位点上游区域甲基化的焦磷酸测序方法。
- BRCA1甲基化在高级别浆液性卵巢癌中检出率为21.5%(17/79)。
- BRCA1甲基化和无残留肿瘤是新辅助化疗后的独立良好预后因素。
核心结论
- BRCA1主要转录起始位点上游区域的甲基化是高级别浆液性卵巢癌患者的独立良好预后因素。
研究设计与样本
- 研究纳入2011至2018年间92例新辅助化疗后的晚期高级别浆液性卵巢癌FFPE样本,进行突变和甲基化分析。
主要发现
- BRCA1甲基化检出17/79(21.5%),BRCA1/2突变检出17/92(18.5%),RAD51C突变检出1/92(1.1%)。
- 单因素分析中,BRCA1甲基化(P=0.025)和无残留肿瘤(P=0.0026)与无进展生存期相关。
- 多因素分析显示,BRCA1甲基化(P=0.038,HR=0.47,95%CI 0.21-0.96)和无残留肿瘤(P=0.012,HR=0.49,95%CI 0.28-0.85)均为显著良好预后因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To establish a quantitative method to evaluate the DNA methylation level of an immediate upstream region of major BRCA1 transcriptional start sites (TSSs), and to investigate whether methylation of the region is a prognostic factor in high-grade serous ovarian cancer patients after neoadjuvant chemotherapy. METHODS: Ninety-two FFPE samples of advanced high-grade serous ovarian cancers after neoadjuvant chemotherapy between 2011 and 2018 were used for mutation and methylation analysis. DNA methylation levels were assessed by pyrosequencing and DNA methylation microarray. An association between methylation level (or a mutation) and progression-free survival was assessed by Kaplan-Meier analysis. RESULT: Major BRCA1 transcripts and CpG sites immediately upstream of their TSSs were identified, and a pyrosequencing method was developed. BRCA1 methylation, BRCA1/2 mutations, and a RAD51C mutation were detected in 17/79 (21.5%), 17/92 (18.5%), and 1/92 (1.1%) high-grade serious ovarian cancer samples. In univariate analysis, BRCA1 methylation and no residual tumor were associated with progression-free survival (BRCA1 methylation: P = 0.025, no residual tumor: P = 0.0026). Multivariate analysis showed that both BRCA1 methylation (P = 0.038, HR = 0.47, 95% CI: 0.21-0.96) and no residual tumor (P = 0.012, HR = 0.49, 95% CI: 0.28-0.85) were significant favorable prognostic factors. CONCLUSION: A quantitative method to estimate the methylation level of the immediate upstream region of major BRCA1 TSSs was established. Methylation of the region of was an independent favorable prognostic factor in high-grade serous ovarian cancer patients.
引用
- Ebata T, Yamashita S, Takeshima H, et al. DNA methylation of the immediate upstream region of BRCA1 major transcription start sites is an independent favorable prognostic factor in patients with high-grade serous ovarian cancer. Gynecol Oncol. 2022. PMID: 36253303. doi:10.1016/j.ygyno.2022.10.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。